Vir enlists J&J vet to run business development; Gilead finds Kite successor to Christi Shaw
→ After grabbing $10 million in funding from the Bill & Melinda Gates Foundation for its HIV vaccine early this month, Vir Biotechnology has now plucked Jeff Calcagno as EVP and CBO. Calcagno hails from J&J, having spent 12 years with the company. Earlier last month, George Scangos handed in his retirement papers and gave the reins of Vir to Bayer’s Marianne De Backer.
→ Gilead has now filled the vacant seat left in the wake of Christi Shaw’s exit from Kite with the appointment of Cindy Perettie. Perettie joins the cell therapy unit as EVP of Kite — instead of CEO — nearly two months after Shaw stepped down, and she will be reporting directly to Daniel O’Day. Perettie formerly served as CEO of Foundation Medicine and later headed Roche’s Molecular Lab Solutions after Roche bought out Foundation.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters